Evidence map›Paper›PMID 25791390›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015

Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.

Diana T Nguyen, Sepideh Shayani, Joycelynne Palmer, Andrew Dagis, Stephen J Forman, Joel Epstein, Ricardo Spielberger

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  2. Trial
  3. Article
  4. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Diana T NguyenDepartment of Pharmacy, City of Hope National Medical Center, Duarte, CA, USA. dtn044@ucsd.edu.
Sepideh ShayaniDepartment of Pharmacy, City of Hope National Medical Center, Duarte, CA, USA.
Joycelynne PalmerDepartment of Biostatistics, City of Hope National Medical Center, Duarte, CA, USA.
Andrew DagisDepartment of Biostatistics, City of Hope National Medical Center, Duarte, CA, USA.
Stephen J FormanDivision of Hematology/HSCT, City of Hope National Medical Center, Duarte, CA, USA.
Joel EpsteinDepartment of Head and Neck Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Ricardo SpielbergerDivision of Hematology/HSCT, City of Hope National Medical Center, Duarte, CA, USA.
City Of Hope National Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study is to assess the impact of palifermin on oral mucositis (OM) and its sequelae in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were conditioned with fractionated total body irradiation (FTBI) and etoposide.

methodsThis retrospective chart review study compared the effect of palifermin on the development of OM in patients who received this agent during an allo-HSCT (n = 99) to those who did not (n = 30). The primary end points were severity and duration of OM. Secondary end points included requirements for opioids, total parenteral nutrition (TPN), and intensive oral care; incidence of infection; length of hospital stay; and overall survival.

resultsThere was no significant difference in the incidence of all grades of OM, but incidence of severe OM was decreased in palifermin-exposed patients (34 vs 80 %, p < 0.0001). In patients who developed OM (all grades), the median duration of OM was shorter in palifermin-exposed patients (13 vs 18 days, p = 0.0001); there was no difference in the median duration of severe OM. Patients who received palifermin used less opioids and required a shorter duration of intensive oral care. There was no difference in duration of TPN, incidence of infection, length of hospital stay, and overall survival.

conclusionsOur findings demonstrated a significant benefit with the use of palifermin for allo-HSCT recipients who were conditioned with FTBI and etoposide. Palifermin can potentially improve quality of life for this patient population and reduce complications and resources used during the transplant process. A randomized clinical trial is required to confirm these results.

Indexed as

AdolescentAdultEtoposideFemaleFibroblast Growth Factor 7Hematopoietic Stem Cell TransplantationHumansIncidenceLength of StayMaleMiddle AgedParenteral Nutrition, TotalQuality of LifeRetrospective StudiesStomatitisWhole-Body IrradiationEtoposideFibroblast Growth Factor 7Allogeneic stem cell transplantFractionated total body irradiationMucositisPaliferminRetrospective

Identifiers

PMID25791390
OpenAlexW2023719692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.